CardiacSense is a pioneering medical technology company focused on developing and commercializing innovative, clinically validated wearable sensors. Their flagship product, a medical-grade watch, provides continuous, long-term monitoring of vital signs including heart rate, atrial fibrillation (AFib), respiratory rate, oxygen saturation (SpO2), and actigraphy. The company aims to revolutionize patient care by enabling early detection of cardiovascular diseases, improving chronic condition management, and facilitating remote patient monitoring for better health outcomes. CardiacSense's technology has received regulatory approvals like FDA clearance and CE marking, underscoring its commitment to clinical accuracy and patient safety.
The Caesarea headquarters serves as the central nervous system for CardiacSense, housing its core operations including research and development, engineering, clinical trial management, regulatory affairs, corporate strategy, and global business administration.
The facility is likely equipped with state-of-the-art R&D laboratories, advanced testing and calibration facilities for medical device development, and modern office spaces designed to foster collaboration and innovation among its multidisciplinary teams.
CardiacSense's work culture is expected to be dynamic, innovative, and mission-driven, with a strong emphasis on scientific rigor, technological excellence, and a patient-first approach. It likely fosters a collaborative environment bringing together experts in engineering, medicine, data science, and business.
The headquarters is paramount to CardiacSense's innovation pipeline, where its proprietary sensor technology and complex algorithms are conceived, developed, and refined. It's the focal point for strategic decision-making, securing intellectual property, and coordinating global market access and commercialization efforts.
CardiacSense primarily operates from its headquarters in Israel. Its global presence is manifested through international clinical research collaborations, regulatory submissions and approvals in key markets such as the United States (FDA) and Europe (CE Mark under MDR), and partnerships with distributors and healthcare providers worldwide to deploy its medical wearable technology. The company actively engages in expanding its market reach to make its continuous monitoring solutions accessible globally.
29 Abba Hillel Silver St., Northern Industrial Park
Caesarea
Caesarea Industrial Park
Israel
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, CardiacSense' leadership includes:
CardiacSense has been backed by several prominent investors over the years, including:
Based on publicly available information and news releases over the past 12 months, there have been no major announcements regarding new executive hires or departures at CardiacSense. The leadership team appears to have maintained stability during this period.
Discover the tools CardiacSense uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
CardiacSense likely utilizes a common professional email format for its employees. While specific patterns can vary, a typical structure would involve the employee's name and the company domain.
[first]@cardiacsense.com
Format
eldad@cardiacsense.com
Example
80%
Success rate
GlobeNewswire • October 26, 2023
CardiacSense announced it has received U.S. Food and Drug Administration (FDA) clearance for its medical watch (CSF-3) for continuous monitoring of Atrial Fibrillation (AFib) and Heart Rate Variability (HRV) by photoplethysmography (PPG). This clearance allows CardiacSense to market and sell its watch in the U.S. for these indications....more
PR Newswire • May 9, 2023
CardiacSense announced it has received CE Mark approval under the new European Medical Device Regulation (MDR) for its medical watch. This allows for the marketing of the device in European Union countries for continuous monitoring of atrial fibrillation, heart rate, heart rate variability, oxygen saturation, respiratory rate, and blood pressure indications....more
NS Medical Devices • July 12, 2023
Following its CE mark approval and progressing towards FDA clearance, CardiacSense is actively preparing for its US market entry with its medical-grade wearable sensor. The company highlighted its advanced technology for continuous patient monitoring, particularly for detecting atrial fibrillation and other key vital signs....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including CardiacSense, are just a search away.